v3.26.3
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)
shares in Millions, $ in Millions
3 Months Ended 9 Months Ended
Sep. 27, 2026
Sep. 28, 2025
Sep. 27, 2026
Sep. 28, 2025
Alliance revenues $ 2,851 $ 2,298 $ 7,888 $ 6,684
Total revenues 16,583 16,654 46,067 45,022
Costs and expenses:        
Cost of sales [1] 4,028 4,172 11,668 10,795
Selling, informational and administrative expenses [1] 3,279 3,186 9,651 9,632
Research and development expenses [1] 3,016 2,546 8,315 7,231
Acquired in-process research and development expenses 669 1,390 822 1,401
Amortization of intangible assets 1,128 1,223 3,497 3,644
Restructuring charges and certain acquisition-related costs 791 286 1,347 945
Other (income)/deductions––net 288 517 4,866 2,210
Income from continuing operations before provision/(benefit) for taxes on income [2] 3,385 3,334 5,902 9,162
Provision/(benefit) for taxes on income 134 (216) 188 (264)
Income from continuing operations 3,251 3,550 5,714 9,427
Discontinued operations––net of tax 0 0 (5) 25
Net income before allocation to noncontrolling interests 3,252 3,550 5,710 9,452
Less: Net income attributable to noncontrolling interests 10 9 29 33
Net income attributable to Pfizer Inc. common shareholders $ 3,242 $ 3,541 $ 5,681 $ 9,419
Earnings per common share––basic:        
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share) $ 0.57 $ 0.62 $ 1.00 $ 1.66
Discontinued operations––net of tax (in dollars per share) 0 0 0 0
Net income attributable to Pfizer Inc. common shareholders (in dollars per share) 0.57 0.62 1.00 1.66
Earnings per common share––diluted:        
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share) 0.56 0.62 0.99 1.65
Discontinued operations––net of tax (in dollars per share) 0 0 0 0
Net income attributable to Pfizer Inc. common shareholders (in dollars per share) $ 0.56 $ 0.62 $ 0.99 $ 1.65
Weighted-average shares--basic (in shares) 5,700 5,685 5,697 5,682
Weighted-average shares--diluted (in shares) 5,751 5,714 5,739 5,710
Product [Member]        
Revenues $ 13,255 $ 13,920 $ 36,833 $ 37,168
Royalty [Member]        
Revenues $ 477 $ 436 $ 1,347 $ 1,170
[1] Exclusive of amortization of intangible assets.
[2] Income from continuing operations before provision/(benefit) for taxes on income.